MedPath

Stratification of Oral Ulcers in Rheumatoid Arthritis Patients Kept on Methotrexate

Completed
Conditions
Methotrexate Adverse Reaction
Oral Mucositis
Interventions
Other: questionnaire
Registration Number
NCT04540250
Lead Sponsor
Beni-Suef University
Brief Summary

This study included rheumatoid arthritis patients receiving Methotrexate as monotherapy. All eligible patients were subjected to thorough clinical examination and full history to identify oral events. Drug history, current dose and duration of MTX were recorded.

Detailed Description

The current study was conducted in the Clinics of Oral Medicine, Faculty of Dentistry and Rheumatology, Faculty of Medicine - Cairo University from 2017 to 2019. This study followed the principles of the Helsinki Declaration and was approved by the Research ethics committee of Faculty of Dentistry, Cairo University.

RA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.

All eligible patients were subjected to thorough clinical examination for the whole oral cavity. Medical history and history of any oral manifestation were recorded. Drug history, dose, and duration of MTX were recorded.

Categorical data was presented as frequencies and percentages. Continuous data was described as means and standard deviations. Means were compared by one-way ANNOVA and Student-t-test. The significance level was set at P ≤0.05. Statistical analysis was performed with IBM® SPSS® Statistics Version 25 for Windows.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
804
Inclusion Criteria
  • patients with Rheumatoid arthritis using methotrexate as sole treatment
Exclusion Criteria
  • patients with Rheumatoid arthritis using any other treatments for Rheumatoid arthritis

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Study group of Rheumatoid arthritis patientsquestionnaireRA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.
Primary Outcome Measures
NameTimeMethod
occurrence of oral mucositisthroughout the study time (one year)

Clinical examination (intra-oral) and history of oral mucositis where recorded

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath